Dosage and Predictors of Naming Treatment Response in Aphasia

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Department of Veterans Affairs
Sponsor:
Information provided by (Responsible Party):
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT02005016
First received: November 14, 2013
Last updated: May 5, 2014
Last verified: May 2014

November 14, 2013
May 5, 2014
October 2013
September 2017   (final data collection date for primary outcome measure)
Philadelphia Naming Test [ Time Frame: This will be administered after completion of intervention, the day after intervention is complete. ] [ Designated as safety issue: No ]
The Philadelphia Naming Test is a performance-based measure commonly used to assess naming (word production) ability among adults with aphasia.
Same as current
Complete list of historical versions of study NCT02005016 on ClinicalTrials.gov Archive Site
Comprehensive Aphasia Test [ Time Frame: This will be administered after completion of intervention, the day after intervention is complete. ] [ Designated as safety issue: No ]
The Comprehensive Aphasia Test is a performance-based measure of language processing across multiple language domains commonly used to assess language-processing ability among adults with aphasia.
Same as current
Not Provided
Not Provided
 
Dosage and Predictors of Naming Treatment Response in Aphasia
Dosage and Predictors of Naming Treatment Response in Aphasia

This study examines aphasia treatment response among veterans living with aphasia. It seeks to identify cognitive and neural factors which are predictive of positive response to treatment targeting naming impairments in aphasia. It also examines the dose-response relationship for naming treatment. More broadly, it seeks to determine who aphasia therapy works best for, and how much aphasia therapy is sufficient to achieve positive treatment response.

Language and communicative impairments following stroke (aphasia) affect more than 30% of stroke survivors, with an incidence of over 180,000 new cases annually. The consequences of aphasia are far reaching and can affect psychosocial adjustment, family role participation, vocational opportunities, and the ability to function independently in society. Recent estimates suggest that VHA outpatient clinics see 2000 new cases of aphasia each year, meaning that approximately 20,000 enrolled VHA patients and 100,000 United States veterans are currently living with the condition. In response to this need, the VA Pittsburgh Healthcare System Geriatric Research, Education, and Clinical Center (GRECC) initiated the Program for Intensive Residential Aphasia Treatment and Education (PIRATE) in January 2009. PIRATE is a clinical demonstration project that provides approximately 100 hours of cognitive-linguistically oriented aphasia treatment to community dwelling veterans over a 4-week period. PIRATE currently serves 18 veterans per year in bi-monthly sessions. Resource limitations associated with PIRATE and aphasia treatment in general require that treatments be offered in the most cost-effective doses to those veterans most likely to benefit from them.

This treatment-effectiveness research study addresses these issues by examining the dose-response relationship for semantically-oriented naming treatment, and identifying cognitive, psycholinguistic and neuroanatomical predictors of treatment success. Study participants (n=60, over a 4-year period) will be recruited nationwide from veterans enrolled in PIRATE. They will have their naming performance measured prior to PIRATE entry, during each week of treatment, and at program exit/follow-up. A battery of cognitive measures and structural magnetic resonance images of their brains will also be collected prior to treatment. Participants' performance on trained and untrained lexical items and a standardized measure of naming performance will be compared across time intervals to specify the therapy amounts for which maximum treatment benefits are achieved. Their treatment outcomes will also be correlated with specific cognitive test scores and the location and extent of their brain lesions to identify cognitive and neurological markers predictive of positive treatment response. Treatment response will also be compared across participants with different psycholinguistic profiles, to determine which groups of patients show greatest benefit from semantically-oriented naming treatment.

This study should provide answers to two interlocking questions: for whom is aphasia therapy most effective, and how much of it is needed to optimize treatment outcomes. These answers have the potential to set transformative new standards for how aphasia treatment is delivered within VHA and to stroke survivors with aphasia more broadly.

Interventional
Phase 1
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Aphasia
  • Stroke
Behavioral: Naming therapy
Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
Other Name: Semantic feature analysis
Experimental: Intervention
All study participants will be assigned to this arm of this single-arm study. Participants will receive intensive behavioral therapy intended to improve their naming (word production) ability.
Intervention: Behavioral: Naming therapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
September 2017
September 2017   (final data collection date for primary outcome measure)

Inclusion Criteria:

All study participants will be community-dwelling adults with aphasia who are accepted into the Program for Intensive Residential Aphasia Treatment and Education (PIRATE) of the VA Pittsburgh Healthcare System (VAPHS). PIRATE participants are veterans, who are referred nationally to VAPHS. Aphasia diagnosis is provided by the referring medical provider, based on performance on standardized aphasia-assessment measures, and will be verified by PIRATE staff prior to enrollment. Diagnosis will be based on clinical impression and performance on the Comprehensive Aphasia Test (CAT).

Study participants must also meet the following inclusion criteria:

  • 18 years of age or older
  • Eligible for participation in the standard PIRATE program
  • Aphasia due to unilateral left hemisphere stroke equal to or more than 6 months post onset
  • Overall CAT mean language modality t-score of less than or equal to 70
  • CAT naming modality t-score greater than or equal to 40
  • No progressive neurological disease or prior central nervous system injury/disorder
  • No severe motor speech disorders (apraxia and/or dysarthria)
  • Learned English as a first language
  • Investigators able to construct lists of sufficient treatment targets and generalization probes based on performance on naming assessments

Exclusion Criteria:

Since study candidates must first be eligible for PIRATE enrollment, the following PIRATE exclusion criteria indirectly apply:

  • Inability to carry out activities of daily living necessary for self-care as determined by an occupational therapy assessment prior to program entry
  • Lack of physical independence
  • History of significant mood or behavioral disorder that is not currently stable/medically managed
  • History of progressive neurological disease
  • History of drug or alcohol dependence that is not currently stable/medically managed
  • Inability to tolerate intensive treatment as determined by previous therapy experiences and tolerance of the intensive initial PIRATE evaluation (2 days of testing)
  • Medical conditions which would preclude independent living as determined by the medical assessment provided by a VAPHS physician prior to program entry
Both
18 Years to 85 Years
No
Contact: Michael W Dickey, PhD Michael.Dickey@va.gov
United States
 
NCT02005016
O0832-R, 1I01RX000832-01A2
No
Department of Veterans Affairs
Department of Veterans Affairs
Not Provided
Principal Investigator: Michael Walsh Dickey, PhD VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Department of Veterans Affairs
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP